autosomal recessive familial Mediterranean fever

Summary

autosomal recessive familial Mediterranean fever (MONDO:0009572) is a disease caused by MEFV (GenCC Definitive), with 1 cohort gene and 59 clinical trials. Top therapeutic interventions include colchicine, anakinra, and rilonacept.

At a glance

• Causal gene: MEFV (GenCC Definitive)
• Cohort genes: 1
• Clinical trials: 59

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	autosomal recessive familial Mediterranean fever
Mondo ID	MONDO:0009572
OMIM	249100
GARD	0024682
Is cancer (heuristic)	no

Also known as: autosomal recessive familial Mediterranean fever · familial Mediterranean fever · familial Mediterranean fever, AR · familial Mediterranean fever, autosomal recessive · FMF

Data availability: 1 GenCC gene-disease record · 9 cell lines.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › autosomal genetic disease › autosomal recessive disease › autosomal recessive familial Mediterranean fever

Related subtypes (218): immunodeficiency-centromeric instability-facial anomalies syndrome, hypercalcemia, infantile, Ochoa syndrome, autosomal recessive Ehlers-Danlos syndrome, vascular type, hydrolethalus syndrome, 3-M syndrome, isolated hyperchlorhidrosis, dacryocystitis-osteopoikilosis syndrome, Hutchinson-Gilford progeria syndrome, achalasia microcephaly syndrome, acrorenal syndrome, autosomal recessive, beta-ketothiolase deficiency, autosomal recessive Alport syndrome, Alstrom syndrome, microphthalmia with limb anomalies, camptodactyly-arthropathy-coxa vara-pericarditis syndrome, Behr syndrome, bifid nose, autosomal recessive, Bloom syndrome, Bowen-Conradi syndrome, camptodactyly with fibrous tissue hyperplasia and skeletal dysplasia, heart defects-limb shortening syndrome, autosomal recessive palmoplantar keratoderma and congenital alopecia, COFS syndrome, craniometaphyseal dysplasia, autosomal recessive, Fraser syndrome, cystic fibrosis, polycystic lipomembranous osteodysplasia with sclerosing leukoencephaly, persistent hyperplastic primary vitreous, autosomal recessive, Donnai-Barrow syndrome, Schöpf-Schulz-Passarge syndrome, cleft lip/palate-ectodermal dysplasia syndrome, Ellis-van Creveld syndrome, Wolcott-Rallison syndrome, autosomal recessive faciodigitogenital syndrome, acromesomelic dysplasia 2B, brittle cornea syndrome, triple-A syndrome, autosomal recessive humeroradial synostosis, multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome, hydrocephalus, nonsyndromic, autosomal recessive 1, autosomal recessive hydrocephalus due to congenital stenosis of aqueduct of Sylvius, hypertelorism, microtia, facial clefting syndrome, hypoparathyroidism-retardation-dysmorphism syndrome, Vici syndrome, Johanson-Blizzard syndrome, autosomal recessive Kenny-Caffey syndrome, Papillon-Lefevre disease, Haim-Munk syndrome, Laurence-Moon syndrome, Donohue syndrome, lipase deficiency, combined, thiamine-responsive megaloblastic anemia syndrome, cartilage-hair hypoplasia, Nijmegen breakage syndrome, pseudo-TORCH syndrome, Galloway-Mowat syndrome, mulibrey nanism, myotonia congenita, autosomal recessive, Schwartz-Jampel syndrome, proteosome-associated autoinflammatory syndrome, Netherton syndrome, Niemann-Pick disease type A, oculodentodigital dysplasia, autosomal recessive, odonto-onycho-dermal dysplasia, autosomal recessive omodysplasia, osteoporosis-pseudoglioma syndrome, Shwachman-Diamond syndrome, phenylketonuria, Bjornstad syndrome, Laron syndrome, autosomal recessive polycystic kidney disease, autosomal recessive inherited pseudoxanthoma elasticum, autosomal recessive multiple pterygium syndrome, rapadilino syndrome, short-rib thoracic dysplasia 9 with or without polydactyly, autosomal recessive Robinow syndrome, Sjogren-Larsson syndrome, scapuloperoneal spinal muscular atrophy, autosomal recessive, spondyloepiphyseal dysplasia tarda, autosomal recessive, inherited threoninemia, Pendred syndrome, autosomal recessive spondylocostal dysostosis, Werner syndrome, ABCD syndrome, Naxos disease, autosomal recessive amelia, human HOXA1 syndromes, sickle cell disease, autosomal recessive proximal renal tubular acidosis, hyper-IgM syndrome type 2, temtamy preaxial brachydactyly syndrome, TH-deficient dopa-responsive dystonia, craniosynostosis syndrome, autosomal recessive, Niemann-Pick disease type B, skin fragility-woolly hair-palmoplantar keratoderma syndrome, CoQ-responsive OXPHOS deficiency, familial adenomatous polyposis 2, Pierson syndrome, palmoplantar keratoderma-XX sex reversal-predisposition to squamous cell carcinoma syndrome, cardiomyopathy-hypotonia-lactic acidosis syndrome, PHARC syndrome, Kahrizi syndrome, cutis laxa with severe pulmonary, gastrointestinal and urinary anomalies, congenital prothrombin deficiency, immunodeficiency 31B, dyskeratosis congenita, autosomal recessive 2, dyskeratosis congenita, autosomal recessive 3, Nestor-Guillermo progeria syndrome, leukoencephalopathy with calcifications and cysts, mitochondrial pyruvate carrier deficiency, branched-chain keto acid dehydrogenase kinase deficiency, dyskeratosis congenita, autosomal recessive 5, hypohidrosis-enamel hypoplasia-palmoplantar keratoderma-intellectual disability syndrome, alacrima, achalasia, and intellectual disability syndrome, hyperlipoproteinemia, type 1D, microcephaly and chorioretinopathy 2, congenital stationary night blindness 1G, combined oxidative phosphorylation deficiency 29, hypermanganesemia with dystonia 2, growth retardation, intellectual developmental disorder, hypotonia, and hepatopathy, gnb5-related intellectual disability-cardiac arrhythmia syndrome, autosomal recessive spastic paraplegia type 78, autosomal recessive limb-girdle muscular dystrophy, Bardet-Biedl syndrome, autosomal recessive cerebellar ataxia, neuronopathy, distal hereditary motor, autosomal recessive, UV-sensitive syndrome, Ehlers-Danlos syndrome, kyphoscoliotic type 1, Cockayne syndrome, hyperphenylalaninemia due to tetrahydrobiopterin deficiency, leukoencephalopathy-palmoplantar keratoderma syndrome, autosomal recessive hypohidrotic ectodermal dysplasia, Warburg micro syndrome, autosomal recessive primary microcephaly, autosomal recessive progressive external ophthalmoplegia, Meier-Gorlin syndrome, autosomal recessive sideroblastic anemia, autosomal recessive intermediate Charcot-Marie-Tooth disease, Perrault syndrome, autosomal recessive hypophosphatemic rickets, de Barsy syndrome, leukocyte adhesion deficiency, Senior-Loken syndrome, autosomal recessive spastic ataxia, childhood-onset autosomal recessive myopathy with external ophthalmoplegia, autosomal recessive cerebral atrophy, GM3 synthase deficiency, autosomal recessive distal renal tubular acidosis, pigmentation defects-palmoplantar keratoderma-skin carcinoma syndrome, autosomal recessive brachyolmia, Aicardi-Goutieres syndrome, homocystinuria without methylmalonic aciduria, Niemann-Pick disease type C, nephronophthisis, autosomal recessive osteopetrosis, peroxisome biogenesis disorder, congenital non-bullous ichthyosiform erythroderma, Seckel syndrome, Usher syndrome, autosomal recessive cutis laxa type 1, autosomal recessive cutis laxa type 2, hearing loss, autosomal recessive, microcephaly, growth restriction, and increased sister chromatid exchange 2, encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 1, congenital vertebral-cardiac-renal anomalies syndrome, hair defect with photosensitivity and intellectual disability syndrome, autosomal recessive severe congenital neutropenia, severe combined immunodeficiency due to CARMIL2 deficiency, extraoral halitosis due to methanethiol oxidase deficiency, neurodevelopmental disorder with microcephaly, impaired language, epilepsy, and gait abnormalities, mitochondrial complex 2 deficiency, nuclear type 3, mitochondrial complex 2 deficiency, nuclear type 4, mismatch repair cancer syndrome, spondyloepimetaphyseal dysplasia with joint laxity, type 3, Kilquist syndrome, Duane anomaly-myopathy-scoliosis syndrome, autosomal recessive axonal charcot-marie-tooth disease due to copper metabolism defect, immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections-lymphopenia syndrome, optic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome, congenital myopathy with reduced type 2 muscle fibers, NAD(P)HX dehydratase deficiency, autosomal recessive ocular albinism, ichthyosis linearis circumflexa, eosinophil peroxidase deficiency, hyperphenylalaninemia due to DNAJC12 deficiency, autosomal recessive epidermolytic ichthyosis, Ehlers-Danlos syndrome, classic-like, 2, joint laxity, short stature, and myopia, HELIX syndrome, auditory neuropathy-optic atrophy syndrome, glycosylphosphatidylinositol biosynthesis defect 15, neurodegeneration, childhood-onset, stress-induced, with variable ataxia and seizures, SCN4A-related myopathy, autosomal recessive, Uner Tan Syndrome, nephropathic cystinosis, Imerslund-Grasbeck syndrome type 1, Imerslund-Grasbeck syndrome type 2, permanent neonatal diabetes mellitus 1, growth hormone insensitivity with immune dysregulation 1, autosomal recessive, Rajab interstitial lung disease with brain calcifications 1, Roberts-SC phocomelia syndrome, neurodevelopmental disorder with microcephaly, impaired language, and gait abnormalities, RPE65-related recessive retinopathy, GUCY2D-related recessive retinopathy, autosomal recessive titinopathy, intellectual disability, autosomal recessive, ALPL-related autosomal recessive hypophosphatasia, spastic paraplegia 18b, autosomal recessive, CEP164-related ciliopathy, RP1-related recessive retinopathy, pseudohypoaldosteronism, type IB2, autosomal recessive, pseudohypoaldosteronism, type IB3, autosomal recessive, spastic paraplegia 30B, autosomal recessive, cerebral arteriopathy, autosomal recessive, with subcortical infarcts and leukoencephalopathy 1, brain small vessel disease 2B, autosomal recessive, IMPG1-related recessive retinopathy, PROM1-related recessive retinopathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 5 · Orphanet: 4 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
MEFV	Definitive	Autosomal recessive	familial Mediterranean fever	5

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
MEFV	Orphanet:117	Behçet disease
MEFV	Orphanet:3243	Sweet syndrome
MEFV	Orphanet:329967	Intermittent hydrarthrosis
MEFV	Orphanet:342	Familial Mediterranean fever

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
MEFV	HGNC:6998	ENSG00000103313	O15553	Pyrin	gencc

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
MEFV	Pyrin	Involved in the regulation of innate immunity and the inflammatory response in response to IFNG/IFN-gamma.

Protein-family classification

Druggable: 0 · Difficult: 1 · Unknown: 0 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Transcription factor	1	8.3×	0.121

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
MEFV	Transcription factor	no		Znf_B-box, B30.2/SPRY, SPRY_dom

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
buccal mucosa cell	1
monocyte	1
mononuclear cell	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
MEFV	153	broad	marker	buccal mucosa cell, monocyte, mononuclear cell

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
MEFV	2,217

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
MEFV	O15553	11

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 11. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Inflammasomes	1	1142.0×	0.005	MEFV
Cell recruitment (pro-inflammatory response)	1	1142.0×	0.005	MEFV
The NLRP3 inflammasome	1	671.8×	0.005	MEFV
Purinergic signaling in leishmaniasis infection	1	423.0×	0.006	MEFV
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways	1	356.9×	0.006	MEFV
Leishmania infection	1	163.1×	0.010	MEFV
Parasitic Infection Pathways	1	163.1×	0.010	MEFV
Innate Immune System	1	25.5×	0.049	MEFV
Infectious disease	1	24.8×	0.049	MEFV
Disease	1	13.1×	0.077	MEFV
Immune System	1	13.0×	0.077	MEFV

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
pyroptosome complex assembly	1	8426.0×	0.002	MEFV
negative regulation of macrophage inflammatory protein 1 alpha production	1	5617.3×	0.002	MEFV
regulation of interleukin-1 beta production	1	2106.5×	0.003	MEFV
negative regulation of interleukin-12 production	1	1053.2×	0.003	MEFV
pattern recognition receptor signaling pathway	1	991.3×	0.003	MEFV
negative regulation of NLRP3 inflammasome complex assembly	1	991.3×	0.003	MEFV
response to type II interferon	1	526.6×	0.004	MEFV
negative regulation of interleukin-1 beta production	1	510.7×	0.004	MEFV
pyroptotic inflammatory response	1	510.7×	0.004	MEFV
negative regulation of cytokine production involved in inflammatory response	1	421.3×	0.004	MEFV
positive regulation of interleukin-1 beta production	1	259.3×	0.006	MEFV
positive regulation of autophagy	1	208.1×	0.007	MEFV
positive regulation of inflammatory response	1	145.3×	0.009	MEFV
negative regulation of inflammatory response	1	137.0×	0.009	MEFV
regulation of gene expression	1	83.4×	0.014	MEFV
inflammatory response	1	37.7×	0.028	MEFV
innate immune response	1	33.6×	0.030	MEFV

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
MEFV	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
MEFV	1	Binding:1

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	MEFV

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
MEFV	1	—

Clinical trials & evidence

Clinical trials

Clinical trials: 59.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	46
PHASE2	8
PHASE4	2
PHASE3	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06666335	PHASE4	NOT_YET_RECRUITING	A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF
NCT02602028	PHASE4	COMPLETED	The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With FMF
NCT06336733	PHASE3	RECRUITING	Randomized Controlled Trial in Patients on Long-term Colchicine With Colchicine-resistant Familial Mediterranean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment for Painful Attacks in Patients Who Refuse Continuous Daily Therapy
NCT01705756	PHASE3	COMPLETED	Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever
NCT05092776	PHASE2	ACTIVE_NOT_RECRUITING	Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine
NCT05190991	PHASE2	RECRUITING	Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever
NCT00094900	PHASE2	COMPLETED	Interleukin-1 Trap to Treat Autoinflammatory Diseases
NCT00582907	PHASE2	COMPLETED	Rilonacept for Treatment of Familial Mediterranean Fever (FMF)
NCT01088880	PHASE2	COMPLETED	Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever
NCT02175589	PHASE2	UNKNOWN	Controlled Ceasing of Colchicine Therapy in Familial Mediterranean Fever (FMF) Patients With Single MEFV (Mediterranean Fever) Gene Mutation
NCT03446209	PHASE2	COMPLETED	Tocilizumab for the Treatment of Familial Mediterranean Fever
NCT05448391	PHASE2	WITHDRAWN	A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF)
NCT01075906	PHASE1	COMPLETED	Pharmacokinetics Study of Colchicine in Familial Mediterranean Fever (FMF) Patients
NCT00001373	Not specified	RECRUITING	Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics
NCT04478409	Not specified	RECRUITING	Characterization of a Functional Test for Mediterranean Family Fever Screening - 2
NCT05292768	Not specified	NOT_YET_RECRUITING	Are Mast Cells Involved in Autoinflammatory Diseases
NCT06257342	Not specified	ACTIVE_NOT_RECRUITING	Physical Abilities of Teenagers With Familial Mediterranean Fever
NCT06338891	Not specified	RECRUITING	Can Gluten/Wheat or Other Foods be Responsible for FMF Attacks
NCT06583304	Not specified	NOT_YET_RECRUITING	Hematological Indices in Pediatric Diagnosed With Familial Mediterranean Fever
NCT06705673	Not specified	NOT_YET_RECRUITING	Gait Profile and Variables in Pediatric Rheumatic Disease Using a Smart Insole System
NCT06725849	Not specified	NOT_YET_RECRUITING	Barriers to Physical Activity in Familial Mediterranean Fever
NCT06743152	Not specified	NOT_YET_RECRUITING	Comparison of the Effects of Synchronous and Asynchronous Telerehabilitation in Patients with Juvenile Familial Mediterranean Fever
NCT06830213	Not specified	NOT_YET_RECRUITING	Investigation of the Validity, Reliability and Responsiveness of the BETY-BQ in FMF
NCT06974942	Not specified	NOT_YET_RECRUITING	Physical Activity in Adolescents With Familial Mediterranean Fever
NCT06981520	Not specified	NOT_YET_RECRUITING	Caspase-1 Activity, IL-1beta, and IL-18 in Patients With FMF
NCT07013045	Not specified	ENROLLING_BY_INVITATION	Comparing Structured Neuromuscular Exercise and Exergaming Program in Adolescents With Familial Mediterranean Fever
NCT07077473	Not specified	RECRUITING	Observing the Efficacy and Safety of Different Drugs Used in Real-world Familial Mediterranean Fever (FMF) Cases
NCT07128225	Not specified	ACTIVE_NOT_RECRUITING	Health-related Quality of Life, Electrocardiographic and Holter Findings in Children With Familial Mediterranean Fever
NCT07129538	Not specified	RECRUITING	Outcomes of Inspiratory Muscle Training in FMF Adolescents
NCT07130305	Not specified	RECRUITING	is There an Effect of Adding Body Vibration to Intake of Vitamin D on Some Outcomes of Familial Mediterranean Fever
NCT07130318	Not specified	RECRUITING	Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Aerobic Exercise
NCT07212764	Not specified	ENROLLING_BY_INVITATION	Mobile App-Based Infection Monitoring in Familial Mediterranean Fever
NCT07329556	Not specified	NOT_YET_RECRUITING	Skin Autofluorescence Assessment of Advanced Glycation End Products in Rheumatic Diseases
NCT07439341	Not specified	NOT_YET_RECRUITING	AGE and CALLY Index in Familial Mediterranean Fever
NCT07517250	Not specified	RECRUITING	A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still’s Disease Patients
NCT00323440	Not specified	WITHDRAWN	Inflammatory Proteins in Familial Mediterranean Fever During Attack and Remission
NCT00658060	Not specified	UNKNOWN	Magnetic Resonance (MR) Spectroscopy In Familial Mediterranean Fever (FMF) Patients
NCT01059279	Not specified	TERMINATED	Heat Intolerance in the Group of FMF Patients
NCT02021084	Not specified	WITHDRAWN	The Effect of Probiotics on Response to Therapy and on Adverse Effect in Patients Treated With Colchicine for Familial Mediterranean Fever.
NCT02466217	Not specified	COMPLETED	Phenomics in Autoimmune and Inflammatory Diseases

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
COLCHICINE	4	4
ANAKINRA	4	3
RILONACEPT	4	2
CANAKINUMAB	4	1
GOFLIKICEPT	3	2
VIMNERIXIN	2	1
CHEMBL5220618	0	2
CHEMBL2368770	0	1